The European cosmetics market offers significant opportunities for international beauty brands. It also requires a level of safety documentation, local responsibility and regulatory coordination that many companies underestimate.
A product that is already sold in the United States, United Kingdom, Asia or the Middle East is not automatically ready for the European Union.
Before a cosmetic product is placed on the EU market, it must have an EU-based Responsible Person, undergo a safety assessment, have a Cosmetic Product Safety Report, maintain a Product Information File and be notified through the Cosmetic Products Notification Portal.
Most launch delays do not begin with a failed laboratory test. They begin with an incomplete formula file, outdated supplier documents, unsupported claims or responsibilities that were never clearly assigned.
Below are ten common cosmetic market-entry mistakes and the practical steps brands can take to avoid them.
1. Assuming that home-market compliance is enough
A cosmetic product may comply with the rules of its existing market and still require substantial changes before it can be launched in the EU.
Different markets can have different requirements relating to:
- prohibited and restricted ingredients
- responsible-person obligations
- safety documentation
- product notification
- ingredient labelling
- warnings and instructions
- claim substantiation
- adverse-effect reporting
US cosmetic companies, for example, may already hold safety-substantiation records and product-listing information under the Modernization of Cosmetics Regulation Act. However, the EU requires a product-specific safety assessment and CPSR before the cosmetic is placed on the market.
What to do: Conduct an EU-specific regulatory gap assessment instead of assuming that an existing compliance file can be transferred unchanged.
2. Appointing the EU Responsible Person too late
Every cosmetic product placed on the EU market must be linked to a Responsible Person established within the EU.
The Responsible Person is not simply a contact address. This party is responsible for ensuring that the product complies with relevant obligations, including safety assessment, product information, notification, labelling and post-market duties.
Brands frequently begin laboratory testing and packaging design before deciding who will perform this role. That creates delays when documents must later be transferred, reviewed or corrected.
What to do: Define the Responsible Person early and clarify who controls the PIF, communicates with authorities and approves product changes.
3. Treating CPNP notification as product approval
The Cosmetic Products Notification Portal is an electronic notification system. It is not an EU approval or certification process.
Once a product has been correctly notified through the CPNP, no additional national cosmetic notification is generally required within the EU. However, the notification does not confirm that the formulation, label, CPSR or claims are compliant.
A product can therefore be successfully entered into the portal and still be non-compliant.
What to do: Complete the safety assessment, documentation review and label check before treating CPNP notification as the final launch step.
4. Starting the CPSR with incomplete supplier documents
A Cosmetic Product Safety Report depends on reliable information about the finished product and its raw materials.
Commonly missing information includes:
- full quantitative formula
- raw-material specifications
- impurity information
- toxicological data
- allergen declarations
- fragrance documentation
- nanomaterial status
- microbiological specifications
- stability information
EU guidance states that the safety assessment should consider hazards arising from raw materials, manufacturing, packaging, microbiological specifications, use conditions and toxicological profiles.
When supplier information is missing, the safety assessor may be unable to reach a defensible conclusion.
What to do: Run a documentation gap check before commissioning the final CPSR.
5. Testing a formulation that is not the final marketed product
Brands sometimes begin microbiological, stability or compatibility testing before the formula is frozen.
Even small changes can affect:
- preservative performance
- product stability
- allergen concentrations
- exposure calculations
- packaging compatibility
- ingredient-list order
- safety conclusions
A test report for one formulation may not automatically support a later version.
What to do: Establish formal formula version control and document whether each change affects existing evidence.
6. Ordering packaging before the final INCI and warning review
Packaging lead times can be long, so companies often approve artwork early. This creates risk when later safety or ingredient reviews change:
- the INCI list
- warnings
- instructions for use
- Responsible Person details
- nominal content
- period-after-opening information
- country-of-origin statements
- product claims
Reprinting packaging can cost more than the safety and compliance work that would have prevented the error.
What to do: Introduce a regulatory artwork approval step before final production.
7. Using one assessment for multiple variants without justification
Product families may contain different:
- fragrances
- colours
- extracts
- active ingredients
- concentrations
- packaging materials
A single assessment may sometimes cover closely related variants, but this must be scientifically justified. A fragrance change can alter the allergen profile, while a colour change can introduce different impurities or restrictions.
What to do: Create a variant matrix showing exactly what changes between each product and which data remain applicable.
8. Developing marketing claims after the product is finished
Claims such as “clinically proven”, “repairs”, “protects”, “reduces irritation” or “supports the skin barrier” may require different types and levels of evidence.
Under EU rules, cosmetic claims must comply with common criteria and remain consistent with the evidence included in the PIF. Claims must not imply that a finished product has an effect merely because one ingredient has that property.
If the claim strategy is developed too late, the available tests may not support the planned communication.
What to do: Define target claims before designing the evidence and testing programme.
9. Confusing safety with market readiness
A product may be considered safe under its intended conditions of use and still not be ready for launch.
Additional problems may include:
- incorrect label information
- unsupported claims
- incomplete PIF documentation
- missing notification
- outdated supplier records
- incorrect Responsible Person details
- language requirements
- inconsistent product variants
Safety assessment is central, but it is only one part of EU market readiness.
What to do: Use a final launch checklist covering safety, documentation, labelling, claims, notification and economic-operator responsibilities.
10. Using disconnected service providers without one project owner
International brands often work separately with:
- a testing laboratory
- a safety assessor
- a Responsible Person
- a regulatory consultant
- a packaging agency
- a manufacturer
- an importer or distributor
Each provider may complete its own task correctly while gaps remain between them.
The laboratory may not know which regulatory question the test is meant to answer. The packaging agency may work with an outdated formula. The safety assessor may receive incomplete testing data.
What to do: Assign one person to manage document versions, dependencies, decisions and handovers across the complete launch process.
A better EU cosmetic market-entry process
A coordinated process should follow these stages:
Phase 1: Product and document assessment
- confirm product classification
- review the formula
- review existing reports
- identify missing supplier information
- define the target EU markets
Phase 2: Testing and safety evidence
- determine which tests are necessary
- avoid unnecessary duplicate testing
- assess whether existing data can be reused
- close safety-data gaps
- prepare the CPSR
Phase 3: Documentation and labelling
- compile or update the PIF
- review ingredient labelling
- verify warnings and instructions
- review product claims
- confirm Responsible Person details
Phase 4: Notification and launch
- complete CPNP notification
- verify packaging consistency
- approve the final product version
- retain a documented market-ready file
Phase 5: Post-market maintenance
- monitor undesirable effects
- assess formula and supplier changes
- update the CPSR and PIF when necessary
- review new regulatory developments
The PIF must be kept for ten years after the last batch is placed on the market and updated when necessary.
How Makrolife supports EU cosmetic market entry
Makrolife helps international cosmetic brands coordinate the scientific and regulatory steps required for EU market entry.
Support may include:
- existing-document review
- formula and supplier-data gap analysis
- testing strategy
- cosmetic safety assessment
- CPSR and PIF preparation
- label and INCI review
- CPNP coordination
- claim-evidence planning
- result interpretation
- post-launch compliance monitoring
The goal is not to repeat every test. It is to identify which information is usable, which information requires updating and which evidence is genuinely missing.
Is your cosmetic product ready for the EU?
Before ordering EU packaging, appointing distributors or confirming a launch date, review the complete product file.
Request an EU Cosmetic Market Entry Gap Assessment from Makrolife.
